About Roel Bulthuis
Form D filings for Ambagon Therapeutics from 2020 to 2022 list Roel Bulthuis as director.
Roel Bulthuis first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Roel Bulthuis in the role, so the role may have started earlier or lasted longer.
Ambagon Therapeutics Inc.
Director
2020 – 2022 · Eindhoven, Netherlands
Develops experimental cancer drugs that stabilize interactions between proteins.
Key Colleagues at Startups
The people Roel Bulthuis works with at each company, as listed on that company's latest Form D.
Ambagon Therapeutics Inc. · Form D/A, Jun 1, 2022
JS
Josh Seidenfeld
Executive officer
MA
Michelle Arkin
Director
PD
Peter Dudek
Director
JN
Janwillem Naesens
Director
MC
Margarita Chavez
Director
NP
Nancy Pryer
Executive officer

Christian Ottmann
Co-Founder & Chief Executive Officer
AR
Adam Rosenberg
Director
MM
Melissa McCracken
Partner, Nextech Invest and director
BM
Bryan Miller
Executive officer
SC
Scott Clarke
Chief Executive Officer and director